Literature DB >> 22561018

Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors.

Preetinder P Singh1, A Gabrielle J van der Kraan, Jiake Xu, Matthew T Gillespie, Julian M W Quinn.   

Abstract

Osteoclast formation is central to bone metabolism, occurring when myelomonocytic progenitors are stimulated by membrane-bound receptor activator of NFκB ligand (RANKL) on osteoblasts. Osteolytic hormones induce osteoblast RANKL expression, and reduce production of RANKL decoy receptor osteoprotegerin (OPG). However, rather than RANKL and OPG mRNA or protein levels, to measure hormonally-induced osteoclastogenic stimuli the net RANKL activity at the osteoblast surface needs to be determined. To estimate this we developed a cell reporter approach employing pre-osteoclast RAW264.7 cells transfected with luciferase reporter constructs controlled by NFκB (NFκB-RAW) or NFATc1 (NFAT-RAW)-binding promoter elements. Strong signals were induced in these cells by recombinant RANKL over 24h. When NFκB-RAW cells were co-cultured on osteoblastic cells (primary osteoblasts or Kusa O cells) stimulated by osteolytic factors 1,25(OH)(2) vitamin D(3) (1,25(OH)(2)D(3)) and prostaglandin E(2) (PGE(2)), a strong dose dependent signal in NFκB-RAW cells was induced. These signals were completely blocked by soluble recombinant RANKL receptor, RANK.Fc. This osteoblastic RANKL activity was sustained for 3 days in Kusa O cells; with 1,25(OH)(2)D(3) withdrawal, RANKL-induced signal was still detectable 24 h later. However, conditioned medium from stimulated osteoblasts induced no signal. TGFβ treatment inhibited osteoclast formation supported by 1,25(OH)(2)D(3)-treated Kusa O cells, and likewise blocked RANKL-dependent signals in NFAT-RAW co-cultured with these cells. These data indicate net RANKL stimulus at the osteoblast surface is increased by 1,25(OH)(2)D(3) and PGE(2), and suppressed by TGFβ, in line with their effects on RANKL mRNA levels. These results demonstrate the utility of this simple co-culture-based reporter assay for osteoblast RANKL activity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561018     DOI: 10.1016/j.bbrc.2012.04.103

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis.

Authors:  Ran Gu; Leilani L Santos; Devi Ngo; HuaPeng Fan; Preetinder P Singh; Gunter Fingerle-Rowson; Richard Bucala; Jiake Xu; Julian M W Quinn; Eric F Morand
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

2.  Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.

Authors:  Luis F de Castro; Andrea B Burke; Howard D Wang; Jeffrey Tsai; Pablo Florenzano; Kristen S Pan; Nisan Bhattacharyya; Alison M Boyce; Rachel I Gafni; Alfredo A Molinolo; Pamela G Robey; Michael T Collins
Journal:  J Bone Miner Res       Date:  2018-11-29       Impact factor: 6.741

3.  Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association.

Authors:  Anthony Martin; Jian Xiong; Theodora Koromila; Jie S Ji; Stephanie Chang; Yae S Song; Jonathan L Miller; Chun-Ya Han; Paul Kostenuik; Susan A Krum; Nyam-Osor Chimge; Yankel Gabet; Baruch Frenkel
Journal:  Bone       Date:  2015-02-17       Impact factor: 4.398

4.  Tensile force on human macrophage cells promotes osteoclastogenesis through receptor activator of nuclear factor κB ligand induction.

Authors:  Chia-Tze Kao; Tsui-Hsien Huang; Hsin-Yuan Fang; Yi-Wen Chen; Chien-Fang Chien; Ming-You Shie; Chia-Hung Yeh
Journal:  J Bone Miner Metab       Date:  2015-07-24       Impact factor: 2.626

5.  A simple and robust reporter gene assay for measuring the bioactivity of anti-RANKL therapeutic antibodies.

Authors:  Chuanfei Yu; Lan Wang; Yongbo Ni; Junzhi Wang
Journal:  RSC Adv       Date:  2019-12-03       Impact factor: 4.036

6.  Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.

Authors:  Xiang-zhou Zeng; Long-gang He; Song Wang; Keng Wang; Yue-yang Zhang; Lei Tao; Xiao-juan Li; Shu-wen Liu
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

7.  A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis.

Authors:  W Kao; R Gu; Y Jia; Xuemin Wei; H Fan; J Harris; Zhiyi Zhang; J Quinn; E F Morand; Y H Yang
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

8.  Macrophage-mediated osteogenesis activation in co-culture with osteoblast on calcium silicate cement.

Authors:  Ming-Gene Tu; Yi-Wen Chen; Ming-You Shie
Journal:  J Mater Sci Mater Med       Date:  2015-11-05       Impact factor: 3.896

9.  Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in human osteoblasts.

Authors:  Yuanyu Zhang; Xia Liu; Kun Li; Jingping Bai
Journal:  Exp Ther Med       Date:  2014-12-22       Impact factor: 2.447

10.  Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling.

Authors:  Shangfu Li; Bu Yang; Dian Teguh; Lin Zhou; Jiake Xu; Limin Rong
Journal:  Int J Mol Sci       Date:  2016-10-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.